Mark James Daniel - 14 Oct 2025 Form 4 Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Role
Chief Financial Officer
Signature
/s/ Mark James Daniel
Issuer symbol
ATOS
Transactions as of
14 Oct 2025
Transactions value $
$0
Form type
4
Filing time
21 Oct 2025, 16:10:03 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Daniel Mark James Chief Financial Officer C/O ATOSSA THERAPEUTICS, INC., 10202 5TH AVENUE NE SUITE 200, SEATTLE /s/ Mark James Daniel 21 Oct 2025 0002092593

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATOS Stock Option (right to buy) Award $0 +578K $0.00 578K 14 Oct 2025 Common Stock 578K $1.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options shall vest with respect to 25% on October 14, 2026, with the remaining 75% to vest in equal quarterly installments over the follwing three years, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.